Abstract:PURPOSE:The deleted in liver cancer-1 (DLC-1) gene that encodes a Rho GTPase-activating protein with tumor suppressor function is located on chromosome 8p21-22, a region frequently deleted in prostate carcinomas. This study was designed to determine whether DLC-1 is deregulated in prostate carcinomas and to assess the contribution of DLC-1 alterations to prostate carcinogenesis.EXPERIMENTAL DESIGN:Primary prostate carcinomas, prostate carcinoma cell lines, benign prostatic hyperplasias, and normal prostatic tissues were examined for detection of functional and structural alterations of the DLC-1 gene by real-time PCR, methylation-specific PCR, and Southern and Western blots.RESULTS:Down-regulation or loss of DCL-1 mRNA expression was detected in 10 of 27 (37%) prostate carcinomas, 3 of 5 (60%) prostate carcinoma cell lines, and 5 of 21 (24%) benign prostatic hyperplasias. DLC-1 promoter methylation was identified in 13 of 27 (48%) prostate carcinomas and 2 matching normal tissues and in 15 of 21 (71%) benign prostatic hyperplasias but was absent in 10 normal prostatic tissues from noncancerous individuals. Genomic deletions were found in only 3 prostate carcinomas and 1 benign prostatic hyperplasia. DLC-1 protein was not detected in 8 of 27 (30%) prostate carcinomas and 11 of 21 (52%) benign prostatic hyperplasias. Methylation of DLC-1 correlated with age in prostate carcinoma patients (P = 0.006) and with prostate-specific antigen blood levels in benign prostatic hyperplasia patients (P = 0.029). Treatment of the three prostate carcinoma cell lines (PC-3, LNCaP, and 22Rv1) expressing a low level of DLC-1 transcripts with inhibitors of DNA methyltransferase or histone deacetylase increased DLC-1 expression.CONCLUSIONS:These results show that the transcriptional silencing of DLC-1 by two epigenetic mechanisms is common and may be involved in the pathogenesis of prostate carcinomas and benign prostatic hyperplasias and could have potential clinical application in the early detection and gene therapy of prostate cancer.

The Research Progress of DLC-1

Research progress on DLC-1, a candidate tumor suppressor gene

Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma

Identification of DLC-1 Expression and Methylation Status in Patients with Non-Small-cell Lung Cancer

DLC-1 is an independent prognostic marker and potential therapeutic target in hepatocellular cancer

Upregulation of DLC-1 Inhibits Pancreatic Cancer Progression: Studies with Clinical Samples and a Pancreatic Cancer Model

Deleted in Liver Cancer-1 Inhibits Cell Growth and Tumorigenicity in Human Pancreatic Cancer

DLC-1 As a Modulator of Proliferation, Apoptosis and Migration in Burkitt’s Lymphoma Cells

Restoration Of Dlc1 Gene Inhibits Proliferation And Migration Of Human Colon Cancer Ht29 Cells

Dlc-1, A Candidate Tumor Suppressor Gene, Inhibits The Proliferation, Migration And Tumorigenicity Of Human Nasopharyngeal Carcinoma Cells

Aberrant Methylation and Deacetylation of Deleted in Liver Cancer-1 Gene in Prostate Cancer: Potential Clinical Applications.

Detection and Clinical Significance of DLC1 Gene Methylation in Serum DNA from Colorectal Cancer Patients

The Tumor Suppressor DLC1 Inhibits Cancer Progression and Oncogenic Autophagy in Hepatocellular Carcinoma

The Correlation Between Expression of DLC-1 and Colon Cancer Staging

Expression of DLC-1 in Hepatocellular Carcinoma

Promoter Methylation and Expression of DLC-1 Gene in Human Colon Cell Lines

Protein expression and promoter methylation of the deleted in liver cancer-1 gene in papillary thyroid carcinoma

Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma.

The Inhibitory Effects of Deleted in Liver Cancer 1 Gene on Gallbladder Cancer Growth Through Induction of Cell Cycle Arrest and Apoptosis

Genetic and Epigenetic Alterations of DLC-1, a Candidate Tumor Suppressor Gene, in Nasopharyngeal Carcinoma.

DLC1 Tumor Suppressor Gene Inhibits Migration and Invasion of Multiple Myeloma Cells Through RhoA GTPase Pathway.